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Frontotemporal lobar degeneration is a highly familial disease and the most common known genetic cause is
the repeat expansionmutation in the gene C9orf72.We have identiﬁed 2 brotherswith an expansionmutation
in C9orf72 using Southern blotting that is undetectable using repeat-primed polymerase chain reaction.
Sequencing using high concentrations of DNA denaturants of a bacterial artiﬁcial chromosome clone obtained
from one of the brothers identiﬁed a 10-base pair deletion adjacent to the expansion that presumably confers
strong secondary structure that interferes with the genotyping. Using an alternative method, we have iden-
tiﬁed missed expansion carriers in our cohort, and this number has increased by approximately 25%. This
observation has important implications for patients undergoing genetic testing for C9orf72.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Frontotemporal lobar degeneration (FTLD) is a common neurode-
generative disease that usually affects people in midlife (Snowden
et al., 2007). It is clinically heterogenous with 3 main subtypes:
behavioral variant frontotemporal dementia (bvFTD), progressive
nonﬂuent aphasia, and semantic dementia. It is also pathologically
heterogenous with about 50% of cases showing neuronal cytoplasmic
inclusions consisting of hyperphosphorylated tau protein. Approxi-
mately 45%of cases haveneuronal cytoplasmic inclusions that lack tau,
but instead contain the DNA- and RNA-binding protein TDP-43. The
remaining 5% cases have inclusions that consist of another DNA- and/
or RNA-binding protein, fused in sarcoma (Mackenzie et al., 2011).viour and Mental Health, AV
, Manchester, M13 9PT, UK.
.
ring-Brown).
Inc. This is an open access article uUp to 40% of patients with FTLD present with a family history of
this disease and in some instances also with amyotrophic lateral
sclerosis (ALS). Much progress in the understanding of the genetic
basis of FTLD has beenmade in the past 15 years, with 3 main genes
causing autosomal dominant forms of disease having been identi-
ﬁed. These are tau gene (Hutton et al., 1998), progranulin (Baker
et al., 2006), and most recently a hexanucleotide repeat expan-
sion in C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011),
the latter being the most common genetic cause of FTLD and ALS
identiﬁed to date. Despite being extremely large, sometimes over
20 kb, the expansion is relatively easy to genotype using repeat-
primed polymerase chain reaction (PCR). This method has been
widely used to establish the frequency of the expansion in pop-
ulations worldwide (Majounie et al., 2012). In addition, this meth-
odology is presently used in a clinical genetics setting to aid
diagnosis of FTLD and ALS. The expansion has been shown to be the
most common in Northern European populations, probably
because of a founder effect (Mok et al., 2012). Currently, 3 potential
mechanisms have been proposed by which the expansion leads tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Southern blot (as of Mann et al. (2013) for Set A and Beck et al. (2013) for Set B)
of C9orf72 of both brothers conﬁrming a repeat expansion is present in both. Set A left
to right, marker; negative control, positive control, patient samples. Set (B) left to right;
marker; patient samples; positive control; negative control.
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nuclear foci, and dipeptide-repeat proteins (DPR) which are repeat
associated non-ATG translated from the expansion (Ash et al., 2013;
Mori et al., 2013).
When establishing the presence and frequency of the C9orf72
repeat expansion in our own clinical and autopsy patient cohorts
with various diseases, we detected 2 patients (brothers, one with
bvFTD and the other ALS) that were positive for DPR pathology in
both cerebral cortex and cerebellum (Supplementary Fig. 1) but had
no expansion when tested with repeat-primed PCR. Despite
repeated re-extraction of DNA from both blood and brain tissues in
both patients, we could not detect more than 6 repeats using pre-
viously published repeat-primed PCR (Renton et al., 2011). Conse-
quently, a Southern blot was performed with DNA extracted from
brain tissue. This showed both patients had an expansion of
approximately 1500e3000 repeats. As the repeat-primed PCR
methodology is currently being used in a clinical genetics setting to
diagnose disease presence in patients and to test family members
for disease risk, it is vital that such methodology is robust in
providing a correct genotype. Here, we describe the characteriza-
tion of the C9orf72 expansion in these 2 patients to understandwhy
we were unable to detect the expansion when using previously
validated repeat-primed PCR (Renton et al., 2011).
2. Methods
All FTLD patients known to harbor a proven mutation MAPT or
GRN were excluded, as were those cases that displayed tau pa-
thology at postmortem. The ﬁnal study group comprised 460 pa-
tients (mean age at onset, 60 years; range, 24e83 years), 244 men
(mean age at onset, 60 years; range, 34e81 years), and 181 women,
(mean age at onset, 59 years; range, 23e83 years). Control cases
were drawn from healthy spouse, 253 being male (mean age,
56 years; range, 30e79 years) and 397 female (mean age, 53 years;
range, 26e81 years). The London cohort consisted of 367 cases of
FTLD (41% female, average onset of 59). All patients and control
subjects were of UK Caucasian ethnic origin and were recruited
with ethical committee approval and provided informed consent.
A bacterial artiﬁcial chromosome (BAC) library was constructed,
from cerebellar tissue from the case of bvFTD described in the
introduction, by Bio S&T Inc (Canada) using the pIndigoBAC-5
vector. This was screened to isolate a BAC clone that contained
C9orf72, and the expansion. Sanger sequencing was performed
using BigDye v3 (Applied Biosystems) run on an ABI 3730 (Applied
Biosystems). One microgram of BAC DNA was included in each re-
action along with 10 pm of primer, 8 mL of BigDye sequencing
master mix v3.1 (Applied Biosystems) in a total volume of 40 mL.
When used, DMSO was added, it was at a ﬁnal concentration of 6%
and betaine at 1 M. Ion torrent next generation sequencing was
performed according to the manufacturer’s instructions (Life
Technology). Southern blot and repeat-primed PCRwere performed
as previously described (Mann et al., 2013; Renton et al., 2011).
3. Results
Our initial thoughts whichmight explain our inability to detect an
expansion in these 2 brothers was that therewas an single nucleotide
polymorphism under the primer used for repeat-primed PCR that lay
outside of the expansion. However, we sequenced this region which
was wild type in both patients (not shown). An expansion in C9orf72Fig. 2. Ten bp deletion adjacent twas conﬁrmed by Southern blotting in both brothers (Fig. 1). To
elucidate as to why the repeat-primed PCR did not detect this, we
attempted to sequence the BAC clone of C9orf72 with the expansion
we had obtained. When we used standard Sanger sequencing with a
primer placed on the telomeric side of the expansion, we obtained
good sequence data that read through some of the expansion and
conﬁrmed it was the usual GGGGCC hexanucleotide repeat
(Supplementary Fig. 2). This also proved that the expansion was not
GC clamping the BAC and preventing polymerase read through.
However, when we placed a primer on the centromeric side of the
repeat and sequenced toward it, the reaction consistently failed to
produce any sequence data, evenwhenwe placed a primer up to 1 kb
away. After ruling out issues of DNA purity, we attempted to use next
generation sequencing (Ion Torrent Personal Genome Machine) to
sequence the entire BAC.We obtained around a 70-fold read depth for
the entire BAC apart from the repeat region where coverage was low,
particularly on the centromeric side. Analysis of this data did not
reveal any differences to the reference genome, Primary Assembly
(GRCh38). Given that Sanger sequencing produced good reads from
the telemetric side of the expansion, but not from the centromeric
side, we hypothesized that a variation in the sequence in this part of
C9orf72 was producing a secondary structure that was preventing
sequencing polymerase read through. We therefore attempted a
Sanger sequencing reactionwith high levels of DNA denaturants (1 M
betaine and 6% DMSO). This produced a good sequence and when
compared with the reference genome (GRCh38 Primary Assembly),
wewere able to detect a 10 bp deletion directly adjacent to the start of
the repeat (Fig. 2). This 10 bp section contains some AT sequence, and
when removed the repeat is then adjacent to more GC rich sequence.
Previously, we had been using the assay of Renton et al. (2011) to
genotype our FTLD and control cohorts and had identiﬁed 37
expansion carriers in the FTLD group. When we repeated the gen-
otyping using the assay of DeJesus-Hernandez et al. (2011) (which
should not be affected by the presence of the deletion; Fig. 3) we
detected a further 11 cases, an increase of approximately 25%. In
addition, we genotyped our ALS cohort (n¼ 234) and the number of
expansion carriers increased from 16 to 20 (Table 1). However,o the GGGGCC repeat region.
Fig. 3. Toperepeat primed PCR showing 6 repeats in C9orf72 using the assay by Renton et al. (2011) in a case with the 10 bp deletion. Bottomethe same case genotyped with the
assay by DeJesus-Hernandez et al. (2011) showing the expansion also shown by Southern blot. Abbreviation: PCR, polymerase chain reaction.
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to detect any additional cases.
In a recent study, Jones et al. (2013) reported that residual
genetic association to chromosome 9p remained, even when
known expansion carriers were removed from their ALS cohort.
When we performed this same analysis in our cohort using
rs10967976 following removal of old and newly identiﬁed
expansion carriers, previous residual association was completely
abolished (Table 2).Table 1
rs10967976 genotype analysis in the Manchester FTLD cohort
rs10967976 Controls (%) FTD all (%) OR 95% CI
All cases
AA 164 (26.54) 106 (24.20) 1.0 d
GA 330 (53.40) 217 (49.54) 1.01 0.75e1.37
GG 124 (20.06) 115 (26.26) 1.43 1.00e2.04
GA þ GG 454 (73.46) 332 (75.80) 1.13 0.85e1.50
AA þ GA 494 (79.94) 323 (73.74) 1.0 d
GG 124 (20.06) 115 (26.26) 1.42 1.06e1.89
Drop “old” expansion cases
AA 164 (26.54) 103 (25.69) 1.0
GA 330 (53.40) 200 (49.88) 0.96 0.71e1.30
GG 124 (20.06) 98 (24.44) 1.26 0.87e1.80
GA þ GG 454 (73.46) 298 (74.31) 1.04 0.78e1.39
AA þ GA 494 (79.94) 303 (75.56) 1.0
GG 124 (20.06) 99 (24.44) 1.28 0.95e1.74
Drop “old” and “new” expansion cases
AA 164 (26.54) 100 (25.64) 1.0
GA 330 (53.40) 198 (50.77) 0.98 0.72e1.33
GG 124 (20.06) 92 (23.59) 1.21 0.84e1.75
GA þ GG 454 (73.46) 290 (74.36) 1.04 0.78e1.39
AA þ GA 494 (79.94) 298 (76.41) 1.0
GG 124 (20.06) 92 (23.59) 1.22 0.90e1.66
Key: CI, conﬁdence interval; FTD, frontotemporal dementia; FTLD, frontotemporal lobar4. Discussion
DRP inclusions are thought to be speciﬁc to C9orf72 expan-
sion carriers; however, there has been some controversy as to
their role in the neurodegenerative process (Mann, 2014).
Nevertheless, they could be considered the equivalent of amyloid
plaques in Alzheimer’s disease with TDP-43 inclusions being the
equivalent neuroﬁbrillary inclusions, and this may account for
the discrepancy of DPR distribution and neurodegeneration. Ourp FTD and/or MND (%) OR 95% CI p
11 (16.92) 1.0 d
0.91 34 (52.31) 1.53 0.75e3.10 0.233
0.045 20 (30.77) 2.40 1.11e5.20 0.026
0.86 54 (83.08) 1.77 0.90e3.47 0.095
45 (69.23) 1.0
0.016 20 (30.77) 1.81 1.00e3.10 0.046
11 (21.15) 1.0
0.817 25 (48.08) 1.12 0.54e2.35 0.745
0.213 16 (30.77) 1.92 0.86e4.29 0.110
0.763 41 (78.85) 1.34 0.67e2.68 0.398
36 (69.23) 1.0
0.099 16 (30.77) 1.77 0.95e3.29 0.071
10 (20.41) 1.0
0.917 25 (51.02) 1.24 0.58e2.64 0.574
0.295 14 (28.57) 1.85 0.79e4.30 0.153
0.768 39 (79.59) 1.40 0.68e2.88 0.349
35 (71.43) 1.0
0.184 14 (28.57) 1.59 0.83e3.20 0.160
degeneration; OR, odds ratio.
Table 2
Frequencies of the original and newly identiﬁed C9orf72 expansion carriers in the
Manchester cohort
Cases C9 carriers old C9 carriers new C9 carriers total
All FTLD, N ¼ 460 37 11 48
FTD þ ALS, N ¼ 74 12 3 15
ALS, N ¼ 234 16 4 20
Key: ALS, amyotrophic lateral sclerosis; FTLD, frontotemporal lobar degeneration.
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DPR inclusions, when no such expansion had been found using
PCR methodology, lead us to reanalyze these cases in depth.
Indeed, Southern blotting revealed an expansion that was un-
detectable using our standard assay (Renton et al., 2011). Sub-
sequently, however, such an expansion became detectable using
the assay of DeJesus-Hernandez et al. (2011). These observations
highlight to need to consider to what extent genetic variation
can affect PCR-based assays and reenforces the utility of relevant
neuropathologic investigation. Sequencing of a BAC cloned from
genomic DNA from one of the individuals identiﬁed a 10 bp
deletion adjacent to the repeat region. A 10 base deletion at this
region has been reported previously but with a normal non-
expanded GGGGCC repeat (van der Zee et al., 2013). However,
the deleted sequence reported by van der Zee et al. (2013) is
reversed when compared with the sequence in the current
genome Primary Assembly (GRCh38). Investigation of alternative
assemblies in the genome databases reveals some heterogeneity
at this locus which could explain these differences. Standard
Sanger sequencing failed to read through the area containing the
deletion in the BAC, and sequence data were only obtained when
strong DNA denaturants were included into the reaction. Pre-
sumably, the deletion confers a strong secondary structure in the
region that prevents polymerase read through. Although de-
naturants are also included into the repeat-primed PCR assay,
the wild-type allele still gets preferentially ampliﬁed and dom-
inates over the mutant.
Using the assay of DeJesus-Hernandez et al. (2011), we could
bypass issues of the deletion affecting genotyping, and in so doing
increased the number of expansion carriers in our cohort by
approximately 25%. There were not any robust clinical differences
between the newly identiﬁed cases and those previously identi-
ﬁed. Nonetheless, other previously undetected carriers were not
identiﬁed in the London cohort, suggesting that the deletion in
combinations with the expansion could be geographically speciﬁc.
The study reported by Jones et al. (2013), reporting residual as-
sociation in C9orf72 following removal of known expansion car-
riers, paradoxically claimed to use the assay of DeJesus-Hernandez
et al. (2011) and therefore should not have been affected by the
10 bp deletion. However, it is possible there is other genetic
variation on the other side of the expansion affecting this assay,
with expansion carriers bearing such a variation again being
missed, and this explaining the residual association. Clearly, local
founder effects do occur as we only ﬁnd the 10 bp deletionwith an
expansion on the same haplotype in cases from the North West of
England all of which could theoretically be distantly related.
However, further genotyping is required to fully establish whether
this is the case. Moreover, there has been a recent report of major
inconsistencies in correctly genotyping cases of known expansion
by different laboratories using local methodologies (Akimoto
et al., 2014). This observation has important implications for pa-
tients undergoing genetic testing for C9orf72, and we would
recommend genotyping samples with both Renton and DeJesus-
Hernandez PCR-based methods to ensure that expansion carriers
do not go undetected.Disclosure statement
The authors have no conﬂicts of interest to disclose.
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